BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27795228)

  • 21. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
    Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
    Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
    Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
    Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
    Shi Q; Li W; Li H; Le Q; Liu S; Zong S; Zheng L; Hou F
    Oncotarget; 2016 Apr; 7(17):24402-14. PubMed ID: 27015550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L; Denaro A; Agustoni F; Bajetta E
    J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
    Navari RM
    Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
    Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
    Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
    Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New antiemetic drugs.
    Roila F; Fatigoni S
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
    Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.